Neurocrine plots 2024 filing for rare disease drug after ‘solid’ PhIII win

Neu­ro­crine’s lead neu­roen­docrinol­o­gy pro­gram has passed its first Phase III test, set­ting up a po­ten­tial FDA fil­ing in 2024.

The San Diego biotech saw its shares $NBIX go up al­most 7% to $117.10 Tues­day on the heels of the an­nounce­ment that crinecer­font met pri­ma­ry and key sec­ondary end­points in the Phase III CAH­t­a­lyst tri­al. The tri­al en­rolled 182 adults with clas­sic con­gen­i­tal adren­al hy­per­pla­sia (CAH) due to 21-hy­drox­y­lase de­fi­cien­cy (21-OHD) — mak­ing it the largest ever in­ter­ven­tion­al tri­al con­duct­ed in this rare dis­ease, ac­cord­ing to the prin­ci­pal in­ves­ti­ga­tor.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.